
ICON Public Limited Company ICLR
$ 113.63
-2.7%
Annual report 2024
added 04-18-2026
ICON Public Limited Company Accounts Payables 2011-2026 | ICLR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 M | 132 M | 81.2 M | 90.8 M | 51.1 M | 24 M | 13.3 M | 18.6 M | 8.7 M | 7.02 M | 2.79 M | 4.59 M | 8.15 M | 5.34 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 M | 2.79 M | 44.3 M |
Quarterly Accounts Payables ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 63.5 M | 90.8 M | 62.6 M | 37.8 M | 48.1 M | 51.1 M | 28.7 M | 32.7 M | 23.3 M | 24 M | 20.8 M | 20.2 M | 19.3 M | 13.3 M | 15.3 M | 15.1 M | 11.8 M | 18.6 M | 13 M | 7.86 M | 13.6 M | 8.7 M | 5.05 M | 6.12 M | 5.65 M | 7.02 M | 4.53 M | 6.3 M | 3.86 M | 2.79 M | 5.91 M | 10.9 M | 6.66 M | 4.59 M | 8.85 M | 11.8 M | 6.79 M | 8.15 M | 9.33 M | 8.07 M | 5.49 M | 5.34 M | 6.52 M | 4.29 M | 8.61 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90.8 M | 2.79 M | 17.6 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
Agilent Technologies
A
|
446 M | $ 115.5 | 0.47 % | $ 35.1 B | ||
|
Celcuity
CELC
|
6.41 M | $ 133.31 | -3.56 % | $ 6.23 B | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
1.88 M | $ 9.61 | 89.55 % | $ 12.8 M | ||
|
Castle Biosciences
CSTL
|
18.7 M | $ 19.6 | -2.73 % | $ 568 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
4.84 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
18.7 M | $ 17.77 | 3.89 % | $ 547 M | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 21.37 | -1.2 % | $ 1.14 B | ||
|
Guardant Health
GH
|
54.4 M | $ 119.71 | 0.63 % | $ 15 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
790 K | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
983 K | $ 1.8 | -1.1 % | $ 7.96 M | ||
|
Illumina
ILMN
|
221 M | $ 144.69 | 0.19 % | $ 23 B | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Lantheus Holdings
LNTH
|
42.9 M | $ 101.47 | -1.49 % | $ 6.85 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 155.9 | -2.74 % | $ 7.73 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 106.55 | 0.31 % | $ 22.8 B | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 429.82 | -0.69 % | $ 12.4 B | ||
|
NeoGenomics
NEO
|
23.1 M | $ 9.33 | 1.08 % | $ 1.2 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 19.06 | -0.1 % | $ 427 M | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
Natera
NTRA
|
31.1 M | $ 198.65 | -2.23 % | $ 19.5 B | ||
|
Myriad Genetics
MYGN
|
30 M | $ 3.86 | 0.92 % | $ 357 M | ||
|
Personalis
PSNL
|
13 M | $ 8.99 | 6.08 % | $ 802 M | ||
|
Senseonics Holdings
SENS
|
4.06 M | $ 6.44 | 1.58 % | $ 269 M | ||
|
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
12.4 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.47 | -0.8 % | $ 5.67 M | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 259.94 | - | $ 21.6 B | ||
|
Twist Bioscience Corporation
TWST
|
11.1 M | $ 64.56 | 6.59 % | $ 3.86 B | ||
|
Thermo Fisher Scientific
TMO
|
3.62 B | $ 448.93 | 0.14 % | $ 169 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.19 | 3.2 % | $ 1.99 B | ||
|
Waters Corporation
WAT
|
104 M | $ 339.53 | -0.83 % | $ 20.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 193.27 | -0.99 % | $ 21.5 B |